BOLD BOUNDLESS BIO INC

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- , (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced an upcoming poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 in Boston, MA.

Details of the presentations are as follows:

Title: Synergistic oral combination of selective RNR inhibitor BBI-825 with selective CHK1 inhibitor BBI-355 targets unique dependencies of oncogene amplified cancers

Abstract Number: LB-A022

Session: Poster Session A

Session Date and Time: Thursday October 23, 2025, 12:30-4:00 PM ET

Location: Level 2, Exhibit Hall D

About Boundless Bio

Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors. Boundless Bio’s research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14% to 17% of cancer patients. Boundless Bio is developing the first ecDNA-directed therapeutic candidates (ecDTx), BBI-355, an oral, selective inhibitor of checkpoint kinase 1 (CHK1), and BBI-825, an oral, selective inhibitor of ribonucleotide reductase (RNR). These compounds are being evaluated in combination in patients with oncogene amplified cancers in the Company’s phase 1/2 POTENTIATE clinical trial. Boundless Bio is conducting IND-enabling studies of another ecDTx, BBI-940, a potentially first-in-class orally bioavailable, selective Kinesin degrader. Boundless Bio is headquartered in San Diego, CA.

For more information, visit  and follow us on  and .

Investor Contacts:

James Lee, Boundless Bio, Inc.

Renee Leck, THRUST Strategic Communications

Media Contact:

Carly Scaduto



EN
13/10/2025

Underlying

BOLDBOUNDLESS BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BOUNDLESS BIO INC

 PRESS RELEASE
Free
BOLD BOUNDLESS BIO I...

Boundless Bio Reports Third Quarter 2025 Financial Results and Busines...

Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights  Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate in the first half of 2026 $118 million in cash supports operations into first half of 2028, through expected proof-of-concept clinical readouts for both programs SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to de...

November 5, 2025 1 EN
 PRESS RELEASE
Free
BOLD BOUNDLESS BIO I...

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EOR...

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- , (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced an upcoming poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 in Boston, MA. Details of t...

October 13, 2025 1 EN
 PRESS RELEASE
Free
BOLD BOUNDLESS BIO I...

Boundless Bio Reports Second Quarter 2025 Financial Results and Busine...

Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment BBI-940 is on track for submission of an investigational new drug application in the first half of 2026 $127 million in cash supports operations into the first half of 2028, throughexpected proof-of-concept clinical readouts for both programs SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) --  , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver tra...

August 5, 2025 1 EN
 PRESS RELEASE
Free
BOLD BOUNDLESS BIO I...

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global H...

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that   Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference. The fireside chat session is scheduled for Monday, June 9, in Miami, FL, ...

June 5, 2025 1 EN
 PRESS RELEASE
Free
BOLD BOUNDLESS BIO I...

Boundless Bio Announces Portfolio Prioritization and Runway Extension

Boundless Bio Announces Portfolio Prioritization and Runway Extension Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first half of 2028, through expected proof-of-concept clinical readouts for each program Conference call and webcast to be held Tuesday, May 27 at 8:00 am ET SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative ...

May 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch